JNJ : Analysis & Opinions

  • Showing 101-200 of 245 items
  • <<
  • 1
  • 2
  • 3
  • >>
  1. Is Controversy About Robot-Assisted Surgery Showing In Intuitive ...

    April 19, 2013
    Uncertainty about procedure growth may be opening a window in these often-expensive shares
  2. Broad Weakness Makes It Harder To Like St. Jude Today

    April 18, 2013
    Although I do believe the long-term expectations for St. Jude are increasingly beatable, this could be a frustrating stock ...
  3. Pharma Is Doing All The Pulling For Johnson & Johnson

    April 17, 2013
    Although JNJ reported decent earnings and has some major new drugs lined up - downside risk is definitely still present.
  4. Pipeline Setback for Idenix - Analyst Blog

    February 7, 2013
    Idenix Pharmaceuticals, Inc. (IDIX) recently announced that the company has decided to discontinue its clinical development ...
  5. P&G Rewards Longs With Better Sales And Stronger Margins

    January 30, 2013
    Procter & Gamble is delivering on its promises for better performances.
  6. What Do All-Time-Highs Indicate For These Stocks Going Forward?

    January 30, 2013
    Some well-known names are making all-time highs, and exhibiting very strong uptrends. The question is where to get in?
  7. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  8. Shabby Reporting And Questionable Prospects At Abbott Labs

    January 28, 2013
    Poor reporting and weak margins undermine the potential of Abbott.
  9. Stryker Follows Its Rivals With A Big Investment In China

    January 22, 2013
    Stryker's acquisition of Trauson is the right deal at the right time.
  10. Data on Novartis' Afinitor - Analyst Blog

    January 14, 2013
    As per recent data published in The Lancet, Novartis' (NVS) cancer drug, Afinitor (everolimus), helped reduce the tumor size ...
  11. Back to Neutral on Bayer - Analyst Blog

    December 26, 2012
    We are reverting to a Neutral recommendation on Bayer (BAYRY) as we believe that all the positive news that led to our previous ...
  12. Gilead Plans to Split Stock 2-for-1 - Analyst Blog

    December 11, 2012
    Recently, the board of directors at Gilead Sciences Inc. (GILD) authorized a two-for-one stock split. The action, which will ...
  13. Hard Times Continue For Align - Analyst Blog

    December 7, 2012
    Investors were left disappointed when Align Technologies (ALGN), a major player in the malocclusion market, announced that ...
  14. Smith & Nephew's Costly Deal

    November 29, 2012
    Smith & Nephew is having to pay a pretty hefty price for this growth injection and this just isn't a sustainable long-term ...
  15. Medtronic's Growth Looks Good, But Can It Last?

    November 22, 2012
    Medtronic may not be a super grower anymore, but it's doing better than the Street seems to acknowledge
  16. Schiff Creates A Bidding War

    November 19, 2012
    Two weeks after Bayer offered to buy Schiff for $34 a share, Reckitt Benckiser is offering $42 a share. A bidding war has ...
  17. Endo Health Solutions Needs Some Solutions Of Its Own

    November 7, 2012
    Can Endo reestablish itself as a quality healthcare name?
  18. Is “Less Bad” As Good As It Gets For Dendreon?

    November 5, 2012
    Dendreon has made progress with its expenses, but the sluggish revenue growth is still the major problem.
  19. GE's Results Reflect An Industrial Slowdown, But Valuation Isn't ...

    October 23, 2012
    GE may have disappointed, but the company and its stock are both in good shape today.
  20. These Companies Have Raised Their Dividends for 50 Consecutive ...

    October 18, 2012
    Imagine if you had bought these stocks 20 years ago. If you had, then right now you'd be earning dividend yields of... 27%... ...
  21. Drugs Have Moved J&J On To A New Phase

    October 17, 2012
    J&J is back on a growth track, but the device business needs fixing.
  22. The Long-Tail Value Of Supreme Brands

    September 25, 2012
    Brand value can make old products into incredible winners.
  23. Valeant Works Its Mojo With Medicis

    September 7, 2012
    Valeant makes a bold but logical bid for Medicis.
  24. Slew of Product Recalls at Covidien - Analyst Blog

    August 24, 2012
    Recently, health care products major Covidien plc. (COV) has been hit by a number of product recalls, the most significant ...
  25. Buffett Sold Almost $3 Billion of these 3 Well-Known Stocks

    August 16, 2012
    As one of the world's most successful and prolific investors, it's no wonder Warren Buffett is closely watched by the stock ...
  26. Pfizer Looks To Spin Off Animal Health Unit

    August 15, 2012
    Pfizer has filed plans to sell up to 20% of its animal-health unit in the first half of 2013 to focus on human pharmaceuticals. ...
  27. The Week Ahead In Healthcare

    August 13, 2012
    The performance of healthcare stocks (as measured by ETFs) has begun to falter a bit, likely in part because Johnson & ...
  28. Stryker Remains Neutral - Analyst Blog

    August 8, 2012
    We reaffirm our Neutral recommendation on Stryker Corp. (SYK). Stryker reported second quarter 2012 adjusted earnings of ...
  29. The Week Ahead In Healthcare

    August 8, 2012
    The week ahead for healthcare stocks.
  30. More Healthy Alternatives To Zimmer

    July 30, 2012
    Zimmer has turned to cost cutting to keep total profit growth moving positively forward, but doesn't appear to have any answers ...
  31. 4 Dividend ETFs With Higher Yields Than LQD

    July 24, 2012
    Once upon a time, the conventional wisdom was that investors should hold stocks as a source of long-term capital appreciation ...
  32. Healthcare Stocks Continuing To Outperform

    July 18, 2012
    These healthcare stocks are still on fire, with potentially more upside left. But is that actually bad for the stock market?
  33. Setback for Chelsea Therapeutics - Analyst Blog

    July 6, 2012
    Chelsea Therapeutics International, Ltd. (CHTP) recently suffered a setback when the US Food and Drug Administration (FDA), ...
  34. Bio-Reference Labs Taking Advantage Of Esoteric Opportunities

    June 22, 2012
    The decision of whether to buy Bio-Reference really comes down to an investor's confidence in the growth prospects for the ...
  35. Integra's New PIP Fixation Device - Analyst Blog

    June 22, 2012
    Medical products company, Integra LifeSciences Holdings Corporation (IART) unveiled its latest device for fixing proximal ...
  36. 3M Set to Acquire FSTech - Analyst Blog

    June 22, 2012
    3M Company (MMM) is all set to acquire business of Federal Signal Technologies Group (FSTech), a provider of electronic toll ...
  37. Covidien Promotes Zogenix's Product - Analyst Blog

    June 8, 2012
    The pharmaceutical unit of Covidien plc (COV) and Zogenix Inc. (ZGNX) have recently agreed to co-endorse a prescription medicine ...
  38. Rockwood Has Its Risks, But Also Some Apparent Value

    May 31, 2012
    Rockwood has economic risks, but offers real growth opporunities in higher-value lithium and ceramics.
  39. 5 Easy Ways to Cash In on US Dividends

    April 26, 2012
    If you’re outside the US looking in, there are important pros and cons to adding exchange traded funds from America to your ...
  40. Beware These Dividend Red Flags

    April 17, 2012
    Companies paying out more than half their earnings or offering very rich yields might be riskier then investors reckon, says ...
  41. 7 Great Names for Dividend Yield

    March 30, 2012
    Large, dividend-paying equities are good portfolio additions in this low-interest-rate environment, says asset manager Chip ...
  42. Ruling Or Not, Healthcare Still Wins

    March 29, 2012
    The Affordable Care Act finally goes in front of the Supreme Court. However, the Justice’s ruling may not matter. Healthcare ...
  43. Dividends That Will Keep Growing

    March 26, 2012
    The value that these companies have created over the years is mainly due to the dividends they pay out to investors.
  44. 5 Reasons to Love Dividend Growth

    March 15, 2012
    What a smart strategy for DIY investors: It’s idiot and inflation proof, it’s money for nothing…and best of all, it works, ...
  45. Birth Control Subsidies Slashed: Will Big Pharma Take A Hit?

    March 6, 2012
    Several states have already slashed birth control subsidies. Learn how this will affect pharmaceutical stocks.
  46. 5 Dow 30 Stocks With Huge Dividends

    February 27, 2012
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  47. The 10 Must-Know Market Forces for 2012

    February 14, 2012
    For the first time since 2007, investors have multiple ways to succeed this year. Understanding how the lingering effects ...
  48. Procter & Gamble Feels The Pinch

    January 31, 2012
    U.S sales growth combined with rising input costs helped put a lid on the company's quarter.
  49. Treat Stocks Like Savings

    January 30, 2012
    These sensible stocks are likely to provide consistent returns, and would have beaten many professional picks during the ...
  50. Colgate-Palmolive Has Growth, But It'll Cost Ya

    January 30, 2012
    Colgate has great growth, but a valuation to match.
  51. Abbott Labs Dividing Its Growth And Income Potential

    January 26, 2012
    With the coming split of operations, Abbott Labs investors will better be able to choose between growth and income.
  52. Stryker Leaning Away From Knees

    January 26, 2012
    A fair amount of future growth is already baked into Stryker’s valuation.
  53. The Long-Term Play In Lab Work

    January 16, 2012
    As drugmakers beef up their pipelines in this world of rising costs, the contract research sector should profit.
  54. A Better ETF for Metals Investors

    January 11, 2012
    The most common silver and gold ETFs may present risks unknown to most investors, says asset manager and analyst Mo Dawoud. ...
  55. Slow And Steady ETFs Outperforming

    January 3, 2012
    Low volatility ETFs lead the way in 2011.
  56. 2011's Biggest Mergers and Acquisitions

    December 30, 2011
    M&A activity rebounded in a big way in 2011. Here's a look back at the biggest mergers and acquisitions during the year.
  57. 2011 - Another Sick Year For Larger Med-Tech

    December 29, 2011
    Larger healthcare companies are still getting sickly returns in the market.
  58. Stryker Falling Back To Earth

    December 16, 2011
    Stryker Corp's stock offers the potential for above-average shareholder returns with modest downside risk.
  59. Uncertainty Still Means Discount For WellPoint

    November 30, 2011
    Uncertainty still means discount for WellPoint.
  60. Solid Dividend-Paying Companies

    November 25, 2011
    If you are looking to add dividends to your portfolio, don't miss these stocks.
  61. Is Third Time The Charm For Gilead?

    November 22, 2011
    Gilead is going all in on Hep C, as it acquires Pharmasset in a massive deal.
  62. Canadians, Look Before You Leap South

    November 22, 2011
    Before painting their portfolios red, white, and blue, Canadian income investors need to understand the drawbacks of playing ...
  63. Covidien Delivers Once Again

    November 21, 2011
    Covidien is overlooked and undervalued.
  64. If CareFusion Can Execute, This Is A Major Bargain

    November 9, 2011
    CareFusion has to make some improvements, but it could really reward investors.
  65. Dendreon's Chinese Water Torture

    November 3, 2011
    Dendreon's Provenge continues to shape up as a major disappointment.
  66. Zimmer Looking To Escape Its Value Trap

    October 31, 2011
    Zimmer continues to trade at a very reasonable forward P/E.
  67. Big Dividends, Small Risk

    October 31, 2011
    Businesses that payout nice dividends can offer reasonable substitutes for some investors.
  68. Stryker Scraping By

    October 24, 2011
    Stryker's growth is modest, but the stock potential is surprising.
  69. Abbott Labs Joins The Separation Movement

    October 24, 2011
    Abbott is joining the separation movement that is sweeping across corporate America. The company plans to break into a medical ...
  70. High Yielding Equities

    October 21, 2011
    Despite the market volatility, there are still some stocks and ETFs that pay above-average dividend yields.
  71. Protect On The Downside With J&J

    October 21, 2011
    J&J trades at a reasonable forward P/E and offers investors downside protection.
  72. Is Jabil Quietly Loading Both Barrels?

    September 30, 2011
    Jabil's revenue is holding up better than its customers.
  73. Berkshire Buys Shares And Controversy

    September 29, 2011
    Berkshire announced its intention to buy back shares, but what does that mean for investors?
  74. Attractive Dividend Stocks To Watch

    September 27, 2011
    Dividend yields, despite how insignificant they may seem, are a major component of equity returns as times goes on
  75. Big Yields In A Low-Rate Environment

    September 12, 2011
    Over a period of years, it's likely that carefully chosen dividend-paying stocks will provide a higher return than Treasuries ...
  76. Medtronic's Healthy Growth Outlook

    August 29, 2011
    Medtronic's stock deserves a close look.
  77. Bonds That Look Better Than Treasuries

    August 14, 2011
    Instability in the political and economic spheres has meant a shift from Treasuries to corporate bonds in recent weeks, writes ...
  78. What Do AA+ And AAA Credit Ratings Mean?

    August 10, 2011
    Whether you held a AAA or AA+ rating, the difference didn't seem to matter to Mr. Market on Monday.
  79. BD Healthy, But No Great Bargain

    August 9, 2011
    BD is not the cheapest health care name, but it comes with a lot of quality.
  80. The Perpetual Boston Scientific Turnaround Story

    August 4, 2011
    Another quarter brings another hope for better days at BSX.
  81. Covidien's Image Starting To Change

    August 3, 2011
    Find out why Covidien is much better than many investors assume.
  82. Better Budgets, Better Times For Robots

    July 12, 2011
    With healthier budgets at hospitals, robots are looking better and better.
  83. Immucor Passes Its Last Test

    July 5, 2011
    Immucor gets a fair price for its shareholders.
  84. Pleasure And Pain For Pfizer

    June 27, 2011
    Pfizer sees a new pain pill make it to market and another sent back to the drawing board.
  85. 10 Drug Stocks for Safety and Yields

    June 26, 2011
    Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the current ...
  86. Dow 30 Stocks With Good Dividends

    June 21, 2011
    For all of you dividend fiends out there, we combed through the Dow 30 to find some of the best yielding stocks...
  87. Johnson & Johnson Surrenders In Stents

    June 17, 2011
    JNJ makes a tough and surprising, but ultimately wise, decision.
  88. Should Investors Worry If Gen-Probe Doesn't Sell Out?

    June 10, 2011
    Not selling may be the best move Gen-Probe can make for its shareholders.
  89. Conglomerates With A Dividend Angle

    June 6, 2011
    Well-run conglomerates can be great additions to income-oriented portfolios.
  90. Medtronic Still Muddling Through

    May 27, 2011
    Medtronic is going nowhere fast, but the quality hasn't left.
  91. Obagi's Pitfalls Provide Investment Opportunity

    May 24, 2011
    Obagi's stock dropped 24% after announcing a 13-cent loss in its first quarter. Find out why this presents an opportunity ...
  92. Mergers In Orthopedics Could Heat Up Stocks

    May 18, 2011
    Major med-tech players have picked up where they left off before the recession and credit crisis.
  93. 4 Stocks Hitting Highs During The Pullback

    May 6, 2011
    Four stocks that are holding up well during a short-term market pullback.
  94. 6 Overbought Stocks To Watch

    April 25, 2011
    Let's take a look at a few stocks that have recently entered overbought territory because these could be candidates for a ...
  95. Despite The Noise, Abbott Still A Value

    April 25, 2011
    Abbott has made some curious moves of late, but the value is still there.
  96. J&J Beats Analyst Expections, But Not Its Rivals

    April 25, 2011
    Tangible signs of sustained sales growth and consistent profit expansion are still absent at J&J.
  97. DexCom Shows Diabetes Still A Growth Industry

    March 9, 2011
    DexCom shows that, although times are tough, people will still adopt better technology.
  98. Multiple Value Creation Opportunities For Stryker

    February 2, 2011
    Stryker could end up being acquired by a larger rival, but company growth trends remain appealingly robust in their own right.
  99. Risk With Little Reward At Johnson & Johnson

    January 27, 2011
    A number of Johnson & Johnson rivals trade at equally appealing valuations and have their acts together in terms of product ...
  100. Unilever: U.K.'s Go-To Company

    January 27, 2011
    Looking ahead, Unilever is in an excellent position to deliver solid growth, cash flow and return on invested capital over ...
  • Showing 101-200 of 245 items
  • <<
  • 1
  • 2
  • 3
  • >>
Trading Center